Bionordika offers transfection reagents from PolyPlus and the NucleofectorTM electroporation technology from Lonza.
The NucleofectorTM Technology, originally introduced into the market by legacy Amaxa in 2001. It enables highly efficient, transfection of primary cells, stem cells, neurons, and cell lines that have traditionally been difficult to transfect via electroporation and other non-viral transfection methods. In recent years, this has opened novel opportunities for disease research and therapeutic development, including the advancement of gene therapies, immunotherapies, and stem cell generation.
Polyplus-transfection® SA is a leading biotechnology company that supports Gene and Cell therapy. Polyplus-transfection’s have 20 years of experience in manufacturing transfection solutions. Polyplus-transfection offers an extensive and growing range of transfection reagents. Polyplus-transfection® is specialized exclusively in transfection from the very beginning. Being experts in the transfection field, Polyplus-transfection® can help you increase efficiency and productivity cutting costs at the same time.